Quest Diagnostics Incorporated (DGX)

NYSE • Healthcare

$233.33

+$2.24 (+1.0%)

Market closed

October 2, 2026 at 20:00 UTC

Open$230.58

Day Range$228.83 - $233.48

Avg. Volume (3M)1.1M

Market Cap$25.7B

P/E Ratio24.5

52 Week Range

$171.18$248.84

Next EarningsIn 18 daysOct 22, 2026

12H

All

02:40:10 UTC

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$3B100%

Gross Profitminus cost of goods$1B34%

Operating Incomeminus R&D and overhead$459M15%

Net Incomeminus taxes and the rest$320M11%

In plain terms: out of every $100 in revenue, Quest Diagnostics Incorporated keeps $11 as net profit.

Fundamentals & Financials

Revenue (TTM)

$11.5B

Net Income (TTM)

$1B

EPS (TTM)

$9.54

ROA (TTM)

6.27%

Current Ratio

1.59

Dividend Yield

0.41%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+1.9%Q3 2025$2.62

+4.0%Q4 2025$2.6

+2.5%Q1 2026$2.42

+5.5%Q2 2026$2.5

+10.6%Q3 2026$3.12

Oct 22

in 18 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +10.6%

Quest Diagnostics beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 23, as revenue rose 10.2% to about $3.0 billion and adjusted EPS came in at $3.12. Revenue of about $3.0 billion topped the $2.97 billion estimate by 2.4%, while adjusted EPS of $3.12 beat the $2.82 estimate by 10.6% and was up from $2.62 a year ago. Net income rose 13.5% to around $320 million, operating income reached roughly $459 million, gross margin held near 34%, and operating margin was about 15%. Operating cash flow was $468 million, and the company repurchased $102 million of stock and paid $96 million in dividends. Consensus for the next period calls for EPS of $2.80 on revenue of $3.03 billion.

Next report — what to expect

Quest Diagnostics (DGX) reports on October 20, 2026. Wall Street is looking for consensus EPS of $2.85 on consensus revenue of $3.04 billion. For trailing context, revenue grew +10.2% year over year last quarter. DGX has beaten EPS in 8 of 8 most recent quarters, so investors may watch whether that pattern continues.

View full earnings history

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated (NYSE: DGX) provides diagnostic information services, risk assessment services, and healthcare information technology in the medical diagnostics and research business. The company generated $11.0 billion of revenue in FY2025. Its work spans routine and advanced clinical testing, anatomic pathology, insurance-focused assessments, and software used by healthcare organizations and clinicians.

Name

Quest Diagnostics Incorporated

CEO

James E. Davis

Website

www.questdiagnostics.com

Industry

Healthcare

Year Founded

1967

Employees

51,500

Today's Snapshot

AI-generated

DGX closed 0.9% above yesterday's close, while its sector was flat. Quest Diagnostics has an upcoming $0.86 dividend, with three days left to qualify.

Trading Volume

Below 10d avg (1.2M)

vs S&P 500 Today

Moderate Outperformance

+0.15%

Updated: October 2, 2026 at 20:22 UTC

Technical Indicators

3 Buy2 Neutral3 Sell

DGX presents a mixed technical picture with the current price near 233.33 sitting below most short- and medium-term averages yet above longer-term moving averages, which creates a balanced, neutral read. Momentum indicators lean soft — negative momentum and a slightly negative MACD — and ADX around 25 suggests a modest directional tendency without clear dominance. Volume-based OBV is negative, adding a downside nuance, while ATR shows moderate volatility. The pivot sits just beneath the market, offering short-term support. Technical takeaway: indicators are split between recent weakness and longer-term support, consistent with a neutral stance.

All signals